- GlobeNewswire•4 days agoRexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
ROCKVILLE, Md., Jan. 20, 2017-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced an ...
- GlobeNewswire•21 days ago
ROCKVILLE, Md., Jan. 03, 2017-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter ...
- GlobeNewswire•3 months ago
Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology Congress. Initiates Stage 2 of the Phase IIa clinical ...
RNN : Summary for Rexahn Pharmaceuticals, Inc. Co - Yahoo Finance
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.17 - 0.18|
|52 Week Range||0.13 - 0.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|